FirsthandHealth
FDA Press AnnouncementsUnited States18 November 2026

FDA approves Infilbray for neurological symptoms of Type 3 Gaucher disease

On November 18, 2026, the U.S. Food and Drug Administration approved Infilbray tablets, known generically as venglustat, for adults and children with Type 3 Gaucher disease who weigh at least 15 kilograms. Type 3 Gaucher disease is a rare inherited disorder where the body fails to break down certain fatty substances, allowing them to collect in organs, tissue, and the brain. This buildup causes progressive problems with coordination, speech, memory, and balance. The FDA granted approval to Genzyme Corporation, a Sanofi company, following a 52-week clinical study of 43 patients aged 12 and older. In the study, patients taking the once-daily oral tablet showed greater improvements on combined measures of coordination and cognitive function than those receiving regular intravenous enzyme replacement infusions. Because the drug crosses the blood-brain barrier, it targets buildup within the nervous system directly. However, the agency noted risks, including serious mood changes and suicidal thinking.

What was announced

The U.S. Food and Drug Administration cleared Infilbray (venglustat) tablets for patients with Type 3 Gaucher disease, or GD3, who weigh at least 15 kilograms (around 33 pounds). The decision covers both pediatric and adult patients. Infilbray was developed by Genzyme Corporation, a Sanofi Company, and reviewed under Priority Review and Orphan Drug designations.

Regulatory clearance rested on a randomized, double-blind clinical study with 43 participants aged 12 and older. Every patient had already achieved systemic disease stability through earlier enzyme replacement therapy. During the trial, one group took oral Infilbray once per day, while the comparison group received intravenous enzyme replacement therapy once every two weeks. After 52 weeks, patients on Infilbray showed better results on combined tests measuring ataxia, which is a loss of muscle control and coordination, and cognitive function.

What it means

GD3 is an inherited genetic condition where a missing or faulty enzyme stops the body from breaking down fatty molecules called glucosphingolipids. Unlike Type 1 Gaucher disease, GD3 involves the brain. Harmful substances accumulate in nervous tissue, causing worsening balance problems, speech difficulties, and memory decline.

Infilbray works by inhibiting glucosylceramide synthase. This action lowers the production of the fatty compounds throughout the body. The tablet passes through the blood-brain barrier, reaching fatty accumulation inside the central nervous system that intravenous enzyme infusions cannot address directly.

Safety data released by the FDA show notable side effects. Frequent issues involve digestive discomfort and changes in mood. Patients also face serious psychiatric risks, including suicidal thoughts and actions. Animal testing also revealed risks of clouded vision in younger subjects and potential harm to developing fetuses during pregnancy.

What the announcement does not tell us

The FDA announcement leaves several practical and clinical details unaddressed:

  • It does not state the price of Infilbray or clarify insurance coverage.
  • Distribution timelines and commercial launch dates are omitted.
  • The trial enrolled only patients aged 12 and older who had already stabilized on enzyme replacement, leaving open how the drug performs in younger children or in patients who have not taken earlier therapy.
  • Detailed rates for adverse effects, including the frequency of mood disorders and gastrointestinal issues, are not provided.
  • Long-term safety beyond the 52-week trial timeline is not detailed.

How this was written

This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is FDA Press Announcements’s own. Always check the original before acting on anything here.

FDA today approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approximately 33 pounds).
Source: FDA Press Announcements

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.